A Phase I/II Study Evaluating The Dosing, Safety, Efficacy, And Biological Activity Of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Neoadjuvant Chemotherapy (NACT) In Patients Actively Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Cancer Read more
A Phase Ib Safety Run-In And Randomized Phase II, Open-Label Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of M6620 In Combination With Avelumab And Carboplatin In Comparison To Standard Of Care Therapy In Participants With Parpi-Resistant Recurrent Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Read more
A Randomized Phase II Trial Of Radiation Therapy And Cisplatin Alone Or In Combination With Intravenous Triapine In Women With Actively Diagnosed Bulky Stage IB2, Stage II, IIIB, Or IVA Cancer Of The Uterine Cervix Or Stage II-IVA Vaginal Cancer Read more
Phase III Randomized Study Of Concurrent Chemotherapy And Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy Read more
A Phase 3, Randomized, Double-Blind Study Of Pembrolizumab Versus Placebo In Combination With Paclitaxel With Or Without Bevacizumab For The Treatment Of Platinum-Resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-Ov65) Read more
A Randomized Phase III, Two-Arm Trial Of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy In Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma Of The Ovary Or Peritoneum Read more
NRG Oncology, Protocol: NRG-GY020, PI: Dr. Mcnamara, Title: A Phase III Randomized Trial Of Radiation +/- Mk-3475 (Pembrolizumab) For Actively Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (Dmmr) Endometrioid Endometrial Cancer Read more
An Open-Label, Randomized Phase 3 Study Of MK-6482 Versus Everolimus In Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 And VEGF-Targeted Therapies Read more
A Phase 2, Randomized, Open-Label Three-Arm Clinical Study To Evaluate The Safety And Efficacy Of Lenvatinib (E7080/MK-7902) In Combination With Pembrolizumab (MK-3475) Versus Standard Of Care Chemotherapy And Lenvatinib Monotherapy In Participants With Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy And Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009) Read more
